<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01787344</url>
  </required_header>
  <id_info>
    <org_study_id>HG-11-02</org_study_id>
    <nct_id>NCT01787344</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial of &quot;Botulax®&quot; to Treat Children With Cerebral Palsy</brief_title>
  <official_title>Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of &quot;Botulax®&quot; Versus &quot;Botox®&quot; in Children With Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of Botulax Inj.®(Botulinum toxin type A, Hugel, South
      Korea) with Botox Inj.® (Botulinum toxin type A, Allergan, USA) in the treatment of cerebral
      palsy in children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with an improvement more than two grade in Physician's Rating Scale score.</measure>
    <time_frame>at 12 weeks post-injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with an improvement more than two grade in Physician's Rating Scale score, comparing to baseline.</measure>
    <time_frame>at 6 and 24weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Passive range of motion, compare to baseline.</measure>
    <time_frame>at 6, 12 and 24 weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Gross Motor Function Measure 88, 66, compare to baseline.</measure>
    <time_frame>at 6, 12 and 24 weeks post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in Modified Tardieu Scale(Ankle DF), compare to baseline.</measure>
    <time_frame>at 6, 12 and 24 weeks post-injection</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Other Infantile Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A (Botulax®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Botulinum toxin type A(Botox®)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A(Botox®)</intervention_name>
    <description>Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units</description>
    <arm_group_label>Botulinum toxin type A(Botox®)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A(Botulax®)</intervention_name>
    <description>Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units</description>
    <arm_group_label>Botulinum toxin type A (Botulax®)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children patients ages from 2years old to 10years old.

          2. Patients who diagnosed with cerebral palsy.

          3. Patients who diagnosed as Gross Motor Function Classification System level I, II, or
             III

          4. Patients who diagnosed as dynamic equinus foot deformity

          5. Patients who agree with participation and signed to written agreement by substitute.
             (Get a signature from children patients if possible)deformity and I, II or III level
             of Gross Motor Function Classification System

        Exclusion Criteria:

          1. Patients who had previous injection of other botulinum toxin products in 3 months

          2. Patients with hypersensitivity history to botulinum toxin products previously

          3. Patients with neuromuscular junction disorder (myasthenia gravis, Lambert- Eaton
             syndrome, or amyotrophic lateral sclerosis, etc.)

          4. Those who have severe cardiovascular, kidney, liver, or respiratory diseases

          5. Those who are taking anticoagulant drugs or have bleeding disorder.

          6. Pratients with treatment of following drugs: Anticonvulsants, tranquilizers,
             narcotics, aminoglycoside antibiotics, muscle relaxtants like baclofen, blockers of
             parasympathetic nervous system, and levodopa.

          7. Patients who had history of surgery, plan to have surgery on legs, foot, or ankle.

          8. Patients who have evidence of fixed contractures regarding to Investigator

          9. Patients who have difference between two legs over 5cm

         10. Patients with severe athetoid movement

         11. Patients who had other treatments related to dynamic equinus foot deformity, such as
             alcohol injection or muscle relaxants

         12. Those who were not enrolled in other studies within 30 days, or were not paseed over 5
             times of half life for clinical trial drugs.

         13. Patients who have possibility to take prevented drugs

         14. Subjects who are not eligible for this study based on investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong-yi Kwon, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center -Seoul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent's hospital</name>
      <address>
        <city>Suwon</city>
        <state>Kyunggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung medical center - Changwon</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic university of Korea, Daejeon St. Mary's hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung medical center - Seoul</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Other Infantile Cerebral Palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

